Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311020 | 0.91 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL1021535 | 0.91 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL1025584 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL1022761 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL1023263 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4311059 | 0.89 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL4310768 | 0.88 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL1021530 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL4315752 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3562619 | 0.86 | CNR1 (0.76) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058264-B2 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| US-7745476-B2 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-29 | — | — | US | claimed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | claimed |
| US-8058264-B2 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-20110053983-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | US | disclosed |
| EP-2274298-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Abbott Healthcare Products B.V. (NL) | 2011-01-19 | — | — | EP | disclosed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7745476-B2 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-29 | — | — | US | disclosed |
| WO-2009130234-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-10-29 | — | — | WO | disclosed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| EP-1713475-B1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1807063-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1713475-A1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2006-10-25 | — | — | EP | disclosed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| WO-2006045799-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005074920-A1 | 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-18 | — | — | WO | disclosed |
| US-20050171179-A1 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885 |
| US-20110053983-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885 |
| US-20050171179-A1 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | CNR2, CNR1, TBXA2R | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.